リヴァプールが188BETと複数年のパートナーシップを再締結

If Javascript is turned off, turn it on. Purpose Impact Domains Drivers Open Search Open Profile Investors Careers Newsroom Contact Us JP EN Open Search Open Products Information Search Close JP EN Purpose Impact Domains Drivers Profile Investors Careers Newsroom Contact Us Using this Website Privacy Policy Site Map Products Information Close Purpose Purpose Impact Domains Drivers Profile Investors Newsroom Purpose Message from Top Management CSV Purpose Long-term Management Vision and Medium-Term Business Plan KIRIN’s HISTORY Corporate Governance Risk Management Value Creation Model About Kirin Group Impact The Origin and Progress of CSV Management CSV Management Management Issues for Sustainable Growth (Group Materiality Matrix) A Responsible Alcohol Producer Health and Well-Being Community Engagement 　Respect for human rights The Environment Other material agenda and governance Domains Product brands Food & Beverages Health Science Pharmaceuticals Drivers Core technology that assures value creation Consumer centric marketing ICT accelerating value creation Diversity and inclusion, culture for innovation Financial strategy Profile Corporate Policy Corporate Overview Management Group Companies Company History Our Approaches in Quality Investors Management Policy Chart Generator Financial Data Non-Financial Information Share-related Information IR Library Individual Investors IR Events Calendar IR website user guide Disclaimer FAQs Third-Party Evaluations Newsroom News Releases Media kit Media Contacts Long-term Management Vision and Medium-Term Business Plan Management Plan Releases and Presentations Value Creation Model Value Creation Story Corporate Governance Overview Management Structure Management, Leadership & Advisory Remuneration System for Executive Officers Risk Management Compliance Kirin Group Tax Policy CSV Management 2022-2024 CSV Commitments Establishment and Operation of the Group CSV Committee Group Sustainability Meetings on Specific Issues Stakeholder Engagement Endorsement and participation in external organizations and initiatives United Nations Global Compact Policies Social contribution activities Sustainable Finance Marketing Communication Policy(MCP) Health and Well-Being What is “Health & Well-being” in Kirin Group? Ensuring food safety and security Ensuring stable supply, safety and reliability as a pharmaceutical company Provide pharmaceuticals for Unmet Medical Needs Support for maintaining the immune system Ensuring occupational health and safety Support for the prevention of non-communicable diseases Implementation of health management Helping to improve the performance of brain function and prevent decline Improvement of access to nutrition Community Engagement Respect for human rights Sustainable development of communities in raw material production areas and business development regions Creating bonds and trust for people's well-being Enhancing the sustainability of food economy Sustainable supply chain Community Topics Respect for human rights Kirin Group Human Rights Policy Embedding the Kirin Group Human Rights Policy in practice Implementing Human Rights Due Diligence The Environment Sustainable use of biological resources Sustainable use of water resources Sustainable recycling of containers and packaging Overcoming climate change Kirin Group's Environmental Vision 2050 Message from Top Management Engagement Vision / Policies / Structure Environmental management and CSV Holistic Environmental Management Information Disclosure Based on the TCFD Framework, TNFD Framework Draft, etc. Our Holistic Approach Third-Party Evaluations of environment Environmental Topics A Responsible Alcohol Producer Dealing with alcohol-related problems Policy and System Food and Beverages Kirin Brewery Company, Limited Lion Pty Ltd Kirin Beverage Company, Limited Mercian Coca-Cola Beverages Northeast, Inc. Health Science domain Message from Senior Executive Officer of Health Science Strategy Kirin Holdings Company, Limited Kyowa Hakko Bio Co., Ltd. Koiwai Dairy Products Co., Ltd. Kirin Beverage Company, Limited Core technology that assures value creation Accelerating intellectual property activities that leverage technological capabilities for the business Diversity and inclusion, culture for innovation Strengthening the human capital capability Diversity Cultivating the organizational culture Corporate Policy Achieving "Joy brings us together" The Story Behind Kirin Beer Labels Corporate Overview Barrier-free route to Kirin Group Head Office Group Companies Kirin Brewery Company, Limited Kirin Beverage Company, Limited Mercian Corporation Company History 1885‐1949 1950‐1989 1990‐1999 2000‐2009 2010‐2019 2020‐ Our Approaches in Quality Quality management Ensuring Product Safety and Reliability in the Food & Beverages Domain Ensuring Product Safety and Reliability in the Health Science Domain Chart Generator Yearly Data Quarterly Data Management Policy Corporate Disclosure Policy Financial Data Message from the Chief Financial Officer Management Analysis Of Financial Position, Operating Results, And Cash Flows Business Segments Consolidated Balance Sheets Consolidated Statements of Income Statements of Cash Flows Non-Financial Information Message from Senior Executive Officer of CSV Strategy ESG Databook Guideline Content Index Share-related Information General Meetings of Shareholders Dividend Payments and Own-share Repurchase Stock Information Share Data Stock Quote Bonds and Rating Analyst Coverage Articles of Incorporation and Regulations Public Notice IR Library Financial Results（Financial Results/Presentations/Financial Statements） IR News Releases IR Events Releases and Presentations Archive Integrated Report Investor’s Guide Market data and Sales Kirin Group Environmental Report Management Plan Releases and Presentations Long-term (Archive) Medium-term (Archive) Current Fiscal Year (Archive) Management Structure Interview with Independent Non-executive Directors 2022-2024 CSV Commitments 2019-2021 CSV Commitments Social contribution activities The Pink Ribbon Activity JICA-KIRIN Fellowship Program Marketing Communication Policy(MCP) Guidelines of Product Labeling Respect for human rights Kirin Group Human Rights Policy Embedding the Kirin Group Human Rights Policy in practice Implementing Human Rights Due Diligence Sustainable development of communities in raw material production areas and business development regions Japanese hops Tea Leaves Vineyards Sustainable supply chain Policy on Sustainable Procurement Activities to Promote Sustainable Procurement Working Together with Suppliers Engagement Dialogue 01 Dialogue 02 Dialogue 03 Dialogue 04 Dialogue 05 Holistic Environmental Management Information Disclosure Based on the TCFD Framework, TNFD Framework Draft, etc. Risks and Opportunities Dealing with alcohol-related problems What is Slow Drinking? Other initiatives in Japan Business Segments Year Quarter Consolidated Balance Sheets Year Quarter Consolidated Statements of Income Year Quarter Statements of Cash Flows Year Quarter General Meetings of Shareholders Previous Fiscal Years Financial Results（Financial Results/Presentations/Financial Statements） Archive IR Events Releases and Presentations Archive KIRIN R＆D DAY 2020 Archive Integrated Report Integrated Report PDF Kirin Integrated Report 2023 Kirin Integrated Report 2022 Kirin Integrated Report 2021 KIRIN CSV REPORT 2020 KIRIN CSV REPORT 2019 KIRIN REPORT 2018 KIRIN REPORT 2016 KIRIN REPORT 2015 Annual Reports (Back numbers) Market data and Sales Domestic sale outline report(Monthly) Domestic Monthly sales report(Archive) Domestic Alcohol market data(Year) Beer consumption by region(Year) Beer consumption by country(Year) Domestic Soft drink market data(Year) Kirin Group Environmental Report Archive Kirin Group Human Rights Policy Feedback from stakeholders during the establishment of the 2018 Human Rights Policy Activities to Promote Sustainable Procurement Past Reports on human rights impact assessments of supply chains JICA-KIRIN Fellowship Program Greetings from the Host Institution Representatives Overview Fellow Introduction About United Nations University-Kirin Fellowship KIRIN CSV REPORT 2020 Message from Top Management Past and Present Special Feature: Growth Strategies for the Health Science Domain Strengthening Organizational Capabilities Financial and Non-financial Highlights Message from the Chief Financial Officer Interview with the Non-executive Director KIRIN CSV REPORT 2019 Message from Top Management Interview with the Chief Financial Officer Strengthening Our Non-Financial Assets CSV Stories CASE1 Pharmaceuticals business CSV Stories CASE2 Businesses bridging Pharmaceuticals and Food & Beverages CSV Stories CASE3 Community Engagement CSV Stories CASE4 The Environment CSV Stories CASE5 A Responsible Alcohol Producer Discussion with Management Interview with an Outside Director Financial and Non-financial Highlights Past and Present KIRIN REPORT 2018 Message from Top Management Discussion with Management, Part1 Discussion with Management, Part2 Interview with an Outside Director CASE1 Kirin Ichiban Shibori Relaunch and Craft Beer Market Development CASE2 Pharmaceuticals for Worldwide Markets CASE3 Lactococcus lactis strain Plasma Stars in New Products CASE4 Advanced High-Efficiency Facilities at Myanmar Brewery History of the Kirin Group The Kirin Group Today Overview by segment and business for fiscal 2017 Management's discussion & analysis Financial & Non-Financial Highlights KIRIN REPORT 2016 To Our Stakeholders Long-Term Management Vision and Medium-Term Business Plan CFO’s Message Overview of the Kirin Group’s Business Kirin’s Foundation for Value Creation Interview with an Outside Director KIRIN REPORT 2015 KEY POINTS ABOUT KIRIN Long-Term Management Vision and Medium-Term Business Plan KIRIN’S GROWTH STRATEGIES A Conversation between Outside Directors Management Issues for Sustainable Growth (Group Materiality Matrix) Technology (R&D) Foundation SCM Foundation Human Resources Foundation Fellow Introduction 2019 Fellow Researchers and Research Themes 2018 Fellow Researchers and Research Themes 2017 Fellow Researchers and Research Themes About United Nations University-Kirin Fellowship List of Former United Nations University-Kirin Fellows Special Feature: Growth Strategies for the Health Science Domain Strategic Decisions in 2019 / Message from the Officer in Charge of Health Business Strategy Part1 Interview with the Executive Officer of R&D Strategy Part2 Creating Synergies with FANCL Corporation Strengthening Organizational Capabilities Enhancing Kirin Beverage's marketing capabilities Development of our human resources Strengthening Our Non-Financial Assets Honkirin and our marketing reform R&D Strategy:Technology creating trusted value Human resources strategies:Diversity and inclusion, culture for innovation Financial & Non-Financial Highlights Financial Highlights Non-Financial Highlights To Our Stakeholders Kirin’s Management Environment,Vision, and Strategies Progress with the Medium-Term Business Plan Issues and Future Initiatives Aiming to Be a Company That Is Completely Trusted Long-Term Management Vision and Medium-Term Business Plan Long-Term Management Vision Medium-Term Business Plan Recognizing the Challenges and Future Initiatives Kirin’s Foundation for Value Creation The Kirin Group’s Value Creation Marketing Research & Development Supply Chain KEY POINTS ABOUT KIRIN Business Structure / Earnings Structure Kirin's History of Progress Long-Term Management Vision and Medium-Term Business Plan Long-Term Management Vision Medium-Term Business Plan List of Former United Nations University-Kirin Fellows 2016 Fellow's Research Projects 2015 Fellow's Research Projects 2014 Fellow's Research Projects 2013 Fellow's Research Projects 2012 Fellow's Research Projects 2011 Fellow's Research Projects 2010 Fellow's Research Projects 2009 Fellow's Research Projects Close [first sentense] Home Investor Relations IR Library KIRIN REPORT [Integrated Report] KIRIN REPORT 2016 Research & Development Print Kirin’s Foundation for Value CreationResearch & Development The Kirin Group’s Value Creation Marketing Research & Development Supply Chain Kirin Group R&D Supporting Sustained Growth Over its long history, Kirin has leveraged its technical expertise to offer consumers products with a variety of added value. By drawing on the fermentation technologies, biotechnologies, and mass production technologies cultivated in the beer business, we advanced into the pharmaceuticals business. Subsequently, Kyowa Hakko Kirin, which was created through a merger with Kyowa Hakko Co., Ltd., joined the Kirin Group. As a result, the Group has a wide range of technical expertise. We are advancing the generation of innovation through effective, efficient R&D resulting from cross-over activities among the six laboratories of Kirin Company’s R&D Division and through R&D based on the self-initiative and mutual collaboration of the category-based and function-based organization, which is the characteristic structure of the R&D Division of Kyowa Hakko Kirin. Furthermore, we are taking on the challenge of creating value that is only available from the Kirin Group by combining the technologies and know-how of both companies. We will further strengthen the technical expertise that is a strength of the Kirin Group and provide new value to society and consumers. The Superiority of Kirin’s R&D Foundation Kirin Company’s R&D Kirin Company’s Research & Development Division conducts R&D with the aim of creating new value in fields centered on food and health and well-being. About 300 researchers reach beyond the walls that separate individual laboratories to combine technologies and ideas and aggressively introduce knowledge from inside and outside the Group. In this way, we are generating a wide range of innovation. Leveraging our strengths, such as the Research Laboratories for Alcoholic Beverage Technologies, which has pilot plants that can accommodate test brewing of a diverse range of beer products, and the Research Laboratories for Packaging Technologies, which conducts in-house development and evaluation of containers and packaging, we rapidly incorporate the results of R&D initiatives into products and services. We have cultivated strengths in our 10 major R&D technologies, and we draw on combinations of various technologies to leverage our strengths in order to create new value with a focus on the future. Kyowa Hakko Kirin’s R&D Kyowa Hakko Kirin is making full use of original R&D capabilities and technical expertise in manufacturing that were cultivated in the field of biopharmaceuticals, as well as open innovation. In this way, the company is implementing new drug discovery activities, centered on four major modalities—therapeutic antibodies, small molecule drugs, nucleic acid drugs, and regenerative therapeutics. Aiming to continue to discover innovative drugs that address unmet medical needs and to be the first to launch them, Kyowa Hakko Kirin is advancing R&D under an integrated system that extends from discovery to development and post-marketing development with a special focus on nephrology, oncology, immunology and allergy, and the central nervous system. Therapeutic antibody manufacturing technologies are one of the representative technologies of Kyowa Hakko Kirin. As a result of many years of biopharmaceutical research, the company has established POTELLIGENT® and COMPLEGENT® technologies, which dramatically enhance the performance of therapeutic antibodies, as well as a technology that enables us to fully generate human antibodies with the same level of diversity as those produced naturally by humans. A consistent research platform and a variety of technologies from creation to improvement of therapeutic antibodies have greatly contributed to our therapeutic antibody development. Initiatives for Further Growth To foster further collaboration between the alcoholic and nonalcoholic beverages businesses and the pharmaceuticals and bio-chemicals businesses, as well as to accelerate the creation of new value through combinations of the technologies possessed by each business, we have commenced initiatives to step up exchange among researchers from Kirin Company and the Kyowa Hakko Kirin Group. We will strive to make steady progress in the collaborative themes of both companies and to achieve concrete research results. In addition, we will implement Open Innovation more aggressively to foster the development, application, and commercialization of promising technologies. Example1:Application of Selected Component Removal Technologies Selected component removal technologies, which are one of our major R&D technologies, are used to selectively remove only unnecessary components while maintaining flavor. Kirin Tanrei Platinum Double, which utilized a world-first technology for the selected removal of the purine body content in happo-shu, has earned strong support from consumers, and sales in 2016 totaled 6.5 million cases, an increase of 6.6% year on year. In addition, through the use of natural adsorbents that selectively adsorb caffeine, our technology for the removal of caffeine from tea while maintaining the flavor, aroma, and other elements of taste of green tea and black tea, received an award from the Japan Soft Drink Association at the 2016 Society of Soft Drink Technologists, Japan. This technology, which has been extended to Kirin Caffeine Zero Nama-cha (a renewal to Kirin Nama-cha Decaffeinated is planned for May 2017) and the Kirin Gogo-no-Kocha Kodawari Sozai series, is contributing to the creation of products that can be consumed with peace of mind by pregnant women and nursing mothers, small children, and other consumers. Example2：Development of Global Strategic Product KRN23 Kyowa Hakko Kirin is developing KRN23 as a global strategic product that will drive gains in global competitiveness. The development of KRN23 began with research focused on phosphorus metabolism.*1 The company subsequently discovered FGF23, a factor involved in diseases such as tumor-induced osteomalacia and X-linked hypophosphatemia (XLH).*2 Utilizing its unique antibody technology, Kyowa Hakko Kirin created KRN23, an antibody that inhibits the activity of FGF23. Kyowa Hakko Kirin not only recognized the scientific significance of the discovery of FGF23 but also created therapeutic candidate KRN23 by utilizing antibody technology. This action was based on the desire of the company to develop novel drugs needed by patients suffering from diseases. In order to achieve sustainable growth in overseas markets, Kyowa Hakko Kirin is advancing Global Phase III Clinical Trials of KRN23 for XLH in such countries as the U.S., Europe, Japan, and South Korea. ※1In addition to absorption and excretion, optimal blood concentration of phosphorus is maintained by metabolic turnover that uses bone as storage. ※2A rare disease that causes bone growth disorder as a result of the onset of hypophosphatemia following the excessive excretion of phosphorus due to high concentrations of FGF23 in the blood. Kirin’s Foundation for Value Creation The Kirin Group’s Value Creation Marketing Research & Development Supply Chain KIRIN REPORT 2016 To Our Stakeholders Long-Term Management Vision and Medium-Term Business Plan CFO’s Message Overview of the Kirin Group’s Business Kirin’s Foundation for Value Creation Interview with an Outside Director Integrated Report Share Please do not forward or share information about alcoholic beverages with anyone under the legal drinking age. Purpose Message from Top Management CSV Purpose Long-term Management Vision and Medium-Term Business Plan KIRIN’s HISTORY Corporate Governance Risk Management Value Creation Model Impact CSV management Management Issues for Sustainable Growth (Group Materiality Matrix) A Responsible Alcohol Producer Health and Well-Being Community Engagement The Environment Other material agenda and governance Domains Product brand Food & Beverages Health Science Pharmaceuticals Drivers Core technology that assures value creation Consumer centric marketing ICT accelerating value creation Diversity and inclusion, culture for innovation Financial Strategy Profile Investors Careers Newsroom Contact Us Terms and Conditions Privacy Policy Site Map You must be of legal drinking age to consume alcohol. Don't drink and drive. Enjoy responsibly. It is advisable not to drink alcohol during pregnancy and breastfeeding. Do not litter! Let's recycle after drinking! © 2007-2024 Kirin Holdings Company, Limited. TOP